IL243189A0 - Preparations containing 1-nk receptor antagonists for the treatment of pruritus - Google Patents

Preparations containing 1-nk receptor antagonists for the treatment of pruritus

Info

Publication number
IL243189A0
IL243189A0 IL243189A IL24318915A IL243189A0 IL 243189 A0 IL243189 A0 IL 243189A0 IL 243189 A IL243189 A IL 243189A IL 24318915 A IL24318915 A IL 24318915A IL 243189 A0 IL243189 A0 IL 243189A0
Authority
IL
Israel
Prior art keywords
serlopitant
pruritus
receptor antagonist
antagonist
receptor
Prior art date
Application number
IL243189A
Other languages
English (en)
Hebrew (he)
Inventor
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
W Larrick James
Original Assignee
Menlo Therapeutics Inc
Zhang Xiaoming
F Schnipper Edward
J Perlman Andrew
W Larrick James
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc, Zhang Xiaoming, F Schnipper Edward, J Perlman Andrew, W Larrick James filed Critical Menlo Therapeutics Inc
Publication of IL243189A0 publication Critical patent/IL243189A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL243189A 2013-06-24 2015-12-17 Preparations containing 1-nk receptor antagonists for the treatment of pruritus IL243189A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
IL243189A0 true IL243189A0 (en) 2016-02-29

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243189A IL243189A0 (en) 2013-06-24 2015-12-17 Preparations containing 1-nk receptor antagonists for the treatment of pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (enExample)
JP (2) JP2016523260A (enExample)
KR (1) KR20160023692A (enExample)
CN (1) CN105473138A (enExample)
AU (2) AU2014302694B2 (enExample)
BR (1) BR112015031724A2 (enExample)
CA (1) CA2915474A1 (enExample)
HK (1) HK1223820A1 (enExample)
IL (1) IL243189A0 (enExample)
MX (2) MX366728B (enExample)
PH (2) PH12015502777A1 (enExample)
RU (1) RU2666219C2 (enExample)
WO (1) WO2014209962A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
JP2009500452A (ja) 2005-07-11 2009-01-08 メルク エンド カムパニー インコーポレーテッド ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法
WO2007044296A2 (en) 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
JP2010502703A (ja) * 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
EP2141992A1 (en) 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Also Published As

Publication number Publication date
MX2015017763A (es) 2016-06-21
BR112015031724A2 (pt) 2017-07-25
RU2666219C2 (ru) 2018-09-06
KR20160023692A (ko) 2016-03-03
JP2016523260A (ja) 2016-08-08
EP3013336A1 (en) 2016-05-04
CN105473138A (zh) 2016-04-06
CA2915474A1 (en) 2014-12-31
AU2014302694B2 (en) 2019-10-17
HK1223820A1 (zh) 2017-08-11
RU2015154037A (ru) 2017-07-28
PH12015502777A1 (en) 2016-03-21
PH12020500255A1 (en) 2021-02-22
MX366728B (es) 2019-07-22
WO2014209962A1 (en) 2014-12-31
MX2019008643A (es) 2019-09-10
AU2014302694A1 (en) 2016-01-07
AU2020200259A1 (en) 2020-02-06
JP2019142960A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
HUS2200048I1 (hu) FcRn antagonisták és alkalmazásaik
IL272279A (en) Chimeric antigen receptor and methods of using it
PT2970473T (pt) Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização
IL243459A0 (en) Targeting of cytokine antagonists
GB201305668D0 (en) Avs6 Integrin Antagonists
EP3020707A4 (en) P2X4 RECEPTOR ANTAGONIST
PL3046885T3 (pl) Dodatek do mielenia cementu umożliwiający stosowanie osprzętu z PCW
IL244356B (en) Formulations for cgrp receptor antagonists
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
ZA201506515B (en) Novel sulfonamide trpa1 receptor antagonists
ZA201604490B (en) S1p3 antagonists
PL2945963T3 (pl) Inhibitory peptydowe nikotynowego receptora acetylocholiny
IL246091A0 (en) Opioid antagonist formulations
ZA201801736B (en) Progesterone receptor antagonist dosage form
TH1501007504A (th) การใช้เซอร์โลพิแทนต์ซึ่งเป็นnk-1 รีเซพเตอร์แอนทาโกนิสต์ ในอาการคัน
GB201304666D0 (en) Dopamine receptor antagonist
GB201402028D0 (en) Comparison tool in respect of WiFi usage in public places
GB201323021D0 (en) Use of kinase inhibitors
GB201321227D0 (en) Use of kinase inhibitors
PH32013000413S1 (en) Stool